We are live on ! Find out more
DARE icon

Dare Bioscience
DARE

13 hedge funds and large institutions have $1.53M invested in Dare Bioscience in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

0.54% more ownership

Funds ownership: 0.14% → 0.68% (+0.54%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

32% less funds holding

Funds holding: 19 → 13 (-6)

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

90% less capital invested

Capital invested by funds: $15.2M → $1.53M (-$13.7M)

Holders
13
Holders Change
-6
Holders Change %
-31.58%
% of All Funds
0.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
3
Reduced
1
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$86.9K
2
Millennium Management
Millennium Management
New York
+$75.3K
3
Goldman Sachs
Goldman Sachs
New York
+$57.2K
4
UBS Group
UBS Group
Switzerland
+$6.47K
5
Deutsche Bank
Deutsche Bank
Germany
+$5.69K

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$39K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$37K
3
TRCT
Tower Research Capital (TRC)
New York
-$12K
4
Northern Trust
Northern Trust
Illinois
-$10K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
PVMCV
1
Polaris Venture Management Co V
Massachusetts
$1.03M – – –
RSCM
2
Rock Springs Capital Management
Maryland
$195K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$185K +$86.9K +1,772 +56%
Millennium Management
4
Millennium Management
New York
$57K +$75.3K +1,535 New
Goldman Sachs
5
Goldman Sachs
New York
$44K +$57.2K +1,166 New
UBS Group
6
UBS Group
Switzerland
$14K +$6.47K +132 +51%
Deutsche Bank
7
Deutsche Bank
Germany
$4K +$5.69K +116 New
AWA
8
Artemis Wealth Advisors
New York
$2.75K – – –
SIAP
9
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$2K – – –
BlackRock
10
BlackRock
New York
$2K +$49 +1 +2%
State Street
11
State Street
Massachusetts
– -$39K -744 Closed
Geode Capital Management
12
Geode Capital Management
Massachusetts
– -$37K -712 Closed
TRCT
13
Tower Research Capital (TRC)
New York
– -$12K -230 Closed
Northern Trust
14
Northern Trust
Illinois
– -$10K -185 Closed
Bank of New York Mellon
15
Bank of New York Mellon
New York
– -$9K -176 Closed
KWM
16
Kingsview Wealth Management
Oregon
– -$5K -89 Closed
Citadel Advisors
17
Citadel Advisors
Florida
– -$4K -84 Closed
Creative Planning
18
Creative Planning
Kansas
– -$2K -42 Closed
Royal Bank of Canada
19
Royal Bank of Canada
Ontario, Canada
– -$392 -8 -53%

DARE Hedge Fund Activity: Q3 2017 in Review

13 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q3 2017, worth a combined $1.53M — down 90% from $15.2M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of DARE and 3 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 3 added.

The largest buyer was Vanguard Group, adding an estimated $86.9K. The largest seller was State Street, exiting entirely with an estimated $39K sold.

  • 13 institutional investors held Dare Bioscience (DARE) as of Q3 2017, down from 19 in Q2 2017.
  • Funds reported $1.53M of Dare Bioscience stock for Q3 2017, down 90% quarter-over-quarter.
  • 3 funds opened new Dare Bioscience positions in Q3 2017 and 8 closed out, a net change of -5 holders.
  • The largest Dare Bioscience buyer in Q3 2017 was Vanguard Group, an estimated $86.9K added.
  • The largest Dare Bioscience seller in Q3 2017 was State Street, an estimated $39K sold.

Based on aggregated 13F filings for Q3 2017.